JP2015507625A5 - - Google Patents

Download PDF

Info

Publication number: JP2015507625A5
Authority: JP; Japan
Prior art keywords: antisense compound; modified; malat; compound according; cancer
Prior art date: 2012-12-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2014548964A

Other languages

English (en)

Japanese (ja)

Other versions

JP6280045B2 (ja

JP2015507625A (ja

Filing date

2012-12-21

Publication date

2016-02-18

2012-12-21 Application filed filed Critical

2012-12-21 Priority claimed from PCT/US2012/071371 external-priority patent/WO2013096837A1/en

2015-03-12 Publication of JP2015507625A publication Critical patent/JP2015507625A/ja

2016-02-18 Publication of JP2015507625A5 publication Critical patent/JP2015507625A5/ja

2018-02-14 Application granted granted Critical

2018-02-14 Publication of JP6280045B2 publication Critical patent/JP6280045B2/ja

Status Active legal-status Critical Current

2032-12-21 Anticipated expiration legal-status Critical

Links

230000000692 anti-sense effect Effects 0.000 claims 21
150000001875 compounds Chemical class 0.000 claims 21
108091007767 MALAT1 Proteins 0.000 claims 8
239000002777 nucleoside Substances 0.000 claims 6
108091034117 Oligonucleotide Proteins 0.000 claims 5
201000011510 cancer Diseases 0.000 claims 3
150000003833 nucleoside derivatives Chemical class 0.000 claims 3
125000003835 nucleoside group Chemical group 0.000 claims 3
208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 2
206010027476 Metastases Diseases 0.000 claims 2
125000002619 bicyclic group Chemical group 0.000 claims 2
230000000295 complement effect Effects 0.000 claims 2
201000005249 lung adenocarcinoma Diseases 0.000 claims 2
LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 1
206010009944 Colon cancer Diseases 0.000 claims 1
208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
241001465754 Metazoa Species 0.000 claims 1
206010060862 Prostate cancer Diseases 0.000 claims 1
208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
208000029742 colonic neoplasm Diseases 0.000 claims 1
201000002313 intestinal cancer Diseases 0.000 claims 1
201000007270 liver cancer Diseases 0.000 claims 1
208000014018 liver neoplasm Diseases 0.000 claims 1
201000005202 lung cancer Diseases 0.000 claims 1
208000020816 lung neoplasm Diseases 0.000 claims 1
230000009401 metastasis Effects 0.000 claims 1
108020004707 nucleic acids Proteins 0.000 claims 1
102000039446 nucleic acids Human genes 0.000 claims 1
150000007523 nucleic acids Chemical class 0.000 claims 1
239000002773 nucleotide Substances 0.000 claims 1
125000003729 nucleotide group Chemical group 0.000 claims 1
102000004169 proteins and genes Human genes 0.000 claims 1
108090000623 proteins and genes Proteins 0.000 claims 1
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1

JP2014548964A 2011-12-22 2012-12-21 肺腺癌内転移関連性転写物１（ｍｅｔａｓｔａｓｉｓ−ａｓｓｏｃｉａｔｅｄ−ｉｎ−ｌｕｎｇ−ａｄｅｎｏｃａｒｃｉｎｏｍａ−ｔｒａｎｓｃｒｉｐｔ−１：ｍａｌａｔ−１）の発現調節法 Active JP6280045B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161579343P	2011-12-22	2011-12-22
US61/579,343		2011-12-22
PCT/US2012/071371 WO2013096837A1 (en)	2011-12-22	2012-12-21	Methods for modulating metastasis-associated-in-lung-adenocarcinoma-transcript-1(malat-1) expression

Publications (3)

Publication Number	Publication Date
JP2015507625A JP2015507625A (ja)	2015-03-12
JP2015507625A5 true JP2015507625A5 (2)	2016-02-18
JP6280045B2 JP6280045B2 (ja)	2018-02-14

Family

ID=48669557

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2014548964A Active JP6280045B2 (ja)	2011-12-22	2012-12-21	肺腺癌内転移関連性転写物１（ｍｅｔａｓｔａｓｉｓ−ａｓｓｏｃｉａｔｅｄ−ｉｎ−ｌｕｎｇ−ａｄｅｎｏｃａｒｃｉｎｏｍａ−ｔｒａｎｓｃｒｉｐｔ−１：ｍａｌａｔ−１）の発現調節法

Country Status (8)

Country	Link
US (1)	US9546368B2 (2)
EP (1)	EP2794880B1 (2)
JP (1)	JP6280045B2 (2)
AU (1)	AU2012358238B2 (2)
CA (1)	CA2859729C (2)
DK (1)	DK2794880T3 (2)
ES (1)	ES2673960T3 (2)
WO (1)	WO2013096837A1 (2)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201322034D0 (en)	2013-12-12	2014-01-29	Almac Diagnostics Ltd	Prostate cancer classification
AU2015214141B2 (en)	2014-02-07	2020-07-30	Katholieke Universiteit Leuven, K.U.Leuven R&D	Inhibition of NEAT1 for treatment of solid tumors
US20170335321A1 (en) *	2014-11-06	2017-11-23	Ibis Biosciences, Inc.	Malat-1, a non-coding rna, is a target for the regulation of learning and memory
WO2018045022A1 (en) *	2016-08-30	2018-03-08	University Of South Florida	Adipose derived stem cell exosomes and uses thereof
CA3043768A1 (en)	2016-11-29	2018-06-07	PureTech Health LLC	Exosomes for delivery of therapeutic agents
CN110225770B (zh)	2016-12-14	2022-04-26	杨森生物科技公司	结合cd8a的纤连蛋白iii型结构域
EP3554561B1 (en)	2016-12-14	2023-06-28	Janssen Biotech, Inc.	Cd137 binding fibronectin type iii domains
EP3554535A4 (en)	2016-12-14	2020-10-21	Janssen Biotech, Inc.	PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
WO2018191153A1 (en) *	2017-04-09	2018-10-18	The Cleveland Clinic Foundation	Cancer treatment by malat1 inhibition
US20190184028A1 (en) *	2017-12-14	2019-06-20	Janssen Biotech, Inc.	Targeting with firbronectin type iii like domain molecules
SG11202100765UA (en)	2018-08-15	2021-03-30	Illumina Inc	Compositions and methods for improving library enrichment
AU2020227824B2 (en) *	2019-02-27	2025-07-10	Ionis Pharmaceuticals, Inc.	Modulators of MALAT1 expression
US11781138B2 (en)	2019-10-14	2023-10-10	Aro Biotherapeutics Company	FN3 domain-siRNA conjugates and uses thereof
WO2021076543A1 (en)	2019-10-14	2021-04-22	Aro Biotherapeutics Company	Epcam binding fibronectin type iii domains
CN119119240A (zh)	2019-10-14	2024-12-13	Aro生物疗法公司	结合cd71的纤维粘连蛋白iii型结构域
EP4229202A4 (en) *	2020-10-13	2025-10-01	Brigham & Womens Hospital Inc	COMPOSITIONS AND METHODS TARGETING CIRC2082 FOR THE TREATMENT OF CANCER
EP4301856A2 (en)	2021-03-05	2024-01-10	ProQR Therapeutics II B.V.	Antisense oligonucleotides for use in the treatment of corneal dystrophies
CA3214552A1 (en)	2021-04-14	2022-10-20	Russell C. Addis	Cd71 binding fibronectin type iii domains
EP4323008A4 (en)	2021-04-14	2026-02-25	Aro Biotherapeutics Company	FN3-ARNSI DOMAIN CONJUGATES AND THEIR USES

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2699808A (en)	1944-10-06	1955-01-18	Mark W Lowe	Apparatus for peeling tomatoes
US2699508A (en)	1951-12-21	1955-01-11	Selectronics Inc	Method of mounting and construction of mounting for low frequency piezoelectric crystals
US5118800A (en)	1983-12-20	1992-06-02	California Institute Of Technology	Oligonucleotides possessing a primary amino group in the terminal nucleotide
FR2567892B1 (fr)	1984-07-19	1989-02-17	Centre Nat Rech Scient	Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US5506337A (en)	1985-03-15	1996-04-09	Antivirals Inc.	Morpholino-subunit combinatorial library and method
US5034506A (en)	1985-03-15	1991-07-23	Anti-Gene Development Group	Uncharged morpholino-based polymers having achiral intersubunit linkages
US5166315A (en)	1989-12-20	1992-11-24	Anti-Gene Development Group	Sequence-specific binding polymers for duplex nucleic acids
US5185444A (en)	1985-03-15	1993-02-09	Anti-Gene Deveopment Group	Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5591722A (en)	1989-09-15	1997-01-07	Southern Research Institute	2'-deoxy-4'-thioribonucleosides and their antiviral activity
DE69034150T2 (de)	1989-10-24	2005-08-25	Isis Pharmaceuticals, Inc., Carlsbad	2'-Modifizierte Oligonukleotide
US5646265A (en)	1990-01-11	1997-07-08	Isis Pharmceuticals, Inc.	Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5670633A (en)	1990-01-11	1997-09-23	Isis Pharmaceuticals, Inc.	Sugar modified oligonucleotides that detect and modulate gene expression
GB9009980D0 (en)	1990-05-03	1990-06-27	Amersham Int Plc	Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
ES2116977T3 (es)	1990-05-11	1998-08-01	Microprobe Corp	Soportes solidos para ensayos de hibridacion de acidos nucleicos y metodos para inmovilizar oligonucleotidos de modo covalente.
EP0538194B1 (de)	1991-10-17	1997-06-04	Novartis AG	Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
US5359044A (en)	1991-12-13	1994-10-25	Isis Pharmaceuticals	Cyclobutyl oligonucleotide surrogates
FR2687679B1 (fr)	1992-02-05	1994-10-28	Centre Nat Rech Scient	Oligothionucleotides.
EP0577558A2 (de)	1992-07-01	1994-01-05	Ciba-Geigy Ag	Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
JPH08504559A (ja)	1992-12-14	1996-05-14	ハネウエル・インコーポレーテッド	個別に制御される冗長巻線を有するモータシステム
CA2159631A1 (en)	1993-03-30	1994-10-13	Sanofi	Acyclic nucleoside analogs and oligonucleotide sequences containing them
US5446137B1 (en)	1993-12-09	1998-10-06	Behringwerke Ag	Oligonucleotides containing 4'-substituted nucleotides
US5519134A (en)	1994-01-11	1996-05-21	Isis Pharmaceuticals, Inc.	Pyrrolidine-containing monomers and oligomers
US5627053A (en)	1994-03-29	1997-05-06	Ribozyme Pharmaceuticals, Inc.	2'deoxy-2'-alkylnucleotide containing nucleic acid
US5597909A (en)	1994-08-25	1997-01-28	Chiron Corporation	Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5656408A (en)	1996-04-29	1997-08-12	Xerox Corporation	Coated carrier particles
US20080119427A1 (en)	1996-06-06	2008-05-22	Isis Pharmaceuticals, Inc.	Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
US6770748B2 (en)	1997-03-07	2004-08-03	Takeshi Imanishi	Bicyclonucleoside and oligonucleotide analogue
JP3756313B2 (ja)	1997-03-07	2006-03-15	武今西	新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6794499B2 (en)	1997-09-12	2004-09-21	Exiqon A/S	Oligonucleotide analogues
JP4236812B2 (ja)	1997-09-12	2009-03-11	エクシコンエ／エス	オリゴヌクレオチド類似体
US6043352A (en)	1998-08-07	2000-03-28	Isis Pharmaceuticals, Inc.	2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
KR20070118315A (ko)	1999-04-21	2007-12-14	와이어쓰	폴리뉴클레오티드 서열의 기능을 억제하기 위한 조성물
US7053207B2 (en)	1999-05-04	2006-05-30	Exiqon A/S	L-ribo-LNA analogues
US6525191B1 (en)	1999-05-11	2003-02-25	Kanda S. Ramasamy	Conformationally constrained L-nucleosides
EP1244667B1 (en)	1999-12-30	2006-04-05	K.U. Leuven Research & Development	Cyclohexene nucleic acids
CA2452458A1 (en)	2001-07-03	2003-01-16	Isis Pharmaceuticals, Inc.	Nuclease resistant chimeric oligonucleotides
EP1540004A4 (en)	2002-07-31	2007-10-03	Nucleonics Inc	DOUBLE-STRING RNA STRUCTURES AND CONSTRUCTS AND METHOD FOR THE PRODUCTION AND USE THEREOF
CA2502649A1 (en)	2002-10-18	2004-04-29	Nucleonics Inc.	Double-stranded rna structures and constructs, and methods for generating and using the same
WO2004041889A2 (en)	2002-11-05	2004-05-21	Isis Pharmaceuticals, Inc.	Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
AU2003291755A1 (en)	2002-11-05	2004-06-07	Isis Pharmaceuticals, Inc.	Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
US6673661B1 (en)	2002-12-20	2004-01-06	Taiwan Semiconductor Manufacturing Co., Ltd.	Self-aligned method for forming dual gate thin film transistor (TFT) device
WO2004106356A1 (en)	2003-05-27	2004-12-09	Syddansk Universitet	Functionalized nucleotide derivatives
EP1661905B9 (en)	2003-08-28	2012-12-19	IMANISHI, Takeshi	Novel artificial nucleic acids of n-o bond crosslinkage type
CA2538252C (en)	2003-09-18	2014-02-25	Isis Pharmaceuticals, Inc.	4'-thionucleosides and oligomeric compounds
WO2006047842A2 (en)	2004-11-08	2006-05-11	K.U. Leuven Research And Development	Modified nucleosides for rna interference
EP1951736A4 (en)	2005-11-21	2009-12-16	Johnson & Johnson Res Pty Ltd	INTERFERING MULTICIBLATION RNA AND METHODS OF USE AND DESIGN
WO2007090071A2 (en)	2006-01-27	2007-08-09	Isis Pharmaceuticals, Inc.	6-modified bicyclic nucleic acid analogs
AU2007249349B2 (en)	2006-05-11	2012-03-08	Isis Pharmaceuticals, Inc.	5'-Modified bicyclic nucleic acid analogs
WO2008101157A1 (en)	2007-02-15	2008-08-21	Isis Pharmaceuticals, Inc.	5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
CA2688321A1 (en)	2007-05-30	2008-12-11	Isis Pharmaceuticals, Inc.	N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
DK2173760T4 (en)	2007-06-08	2016-02-08	Isis Pharmaceuticals Inc	Carbocyclic bicyclic nukleinsyreanaloge
AU2008272918B2 (en)	2007-07-05	2012-09-13	Isis Pharmaceuticals, Inc.	6-disubstituted bicyclic nucleic acid analogs
WO2009067647A1 (en)	2007-11-21	2009-05-28	Isis Pharmaceuticals, Inc.	Carbocyclic alpha-l-bicyclic nucleic acid analogs
WO2009100320A2 (en)	2008-02-07	2009-08-13	Isis Pharmaceuticals, Inc.	Bicyclic cyclohexitol nucleic acid analogs
DK2356129T3 (da)	2008-09-24	2013-05-13	Isis Pharmaceuticals Inc	Substituerede alpha-L-bicykliske nukleosider
DK2361256T3 (da)	2008-09-24	2013-07-01	Isis Pharmaceuticals Inc	Cyclohexenyl-nukleinsyreanaloger
AT507215B1 (de)	2009-01-14	2010-03-15	Boehler Edelstahl Gmbh & Co Kg	Verschleissbeständiger werkstoff
US20120021515A1 (en)	2009-02-06	2012-01-26	Swayze Eric E	Oligomeric compounds and methods
US9012421B2 (en)	2009-08-06	2015-04-21	Isis Pharmaceuticals, Inc.	Bicyclic cyclohexose nucleic acid analogs
WO2011130742A2 (en)	2010-04-16	2011-10-20	Wisconsin Alumni Research Foundation	Diagnostic evaluation of antibody responses to commonly recognized prostate cancer-associated antigens
EP2601204B1 (en)	2010-04-28	2016-09-07	Ionis Pharmaceuticals, Inc.	Modified nucleosides and oligomeric compounds prepared therefrom
EP2595663A4 (en)	2010-07-19	2014-03-05	Isis Pharmaceuticals Inc	MODULATION OF DYSTROPHIA MYOTONICA PROTEIN KINASE (DMPK) EXPRESSION
US9984408B1 (en)	2012-05-30	2018-05-29	Amazon Technologies, Inc.	Method, medium, and system for live video cooperative shopping
US9778708B1 (en)	2016-07-18	2017-10-03	Lenovo Enterprise Solutions (Singapore) Pte. Ltd.	Dual sided latching retainer for computer modules

2012
- 2012-12-21 AU AU2012358238A patent/AU2012358238B2/en active Active
- 2012-12-21 ES ES12860563.1T patent/ES2673960T3/es active Active
- 2012-12-21 CA CA2859729A patent/CA2859729C/en active Active
- 2012-12-21 US US14/368,269 patent/US9546368B2/en active Active
- 2012-12-21 WO PCT/US2012/071371 patent/WO2013096837A1/en not_active Ceased
- 2012-12-21 DK DK12860563.1T patent/DK2794880T3/en active
- 2012-12-21 EP EP12860563.1A patent/EP2794880B1/en active Active
- 2012-12-21 JP JP2014548964A patent/JP6280045B2/ja active Active

Publication	Publication Date	Title
JP2015507625A5 (2)	2016-02-18
JP2013226147A5 (2)	2014-03-13
JP2016116520A5 (2)	2016-08-12
JP2014511686A5 (2)	2015-04-09
RU2017120536A (ru)	2018-11-14	Способы и композиции для модулирования экспрессии аполипопротеина (а)
JP2012505660A5 (2)	2012-11-29
JP2016501513A5 (2)	2016-12-01
NZ710192A (en)	2017-02-24	Modulation of apolipoprotein ciii (apociii) expression
JP2018199700A5 (2)	2019-02-07
EA201200217A1 (ru)	2012-12-28	Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков
JP2015501155A5 (2)	2015-12-10
JP2016513976A5 (2)	2017-04-20
HRP20200042T1 (hr)	2020-03-20	Suprotne nukleinske kiseline za uporabu u liječenju duchennove mišićne distrofije
JP2017510271A5 (2)	2018-04-26
JP2018528781A5 (2)	2020-11-12
JP2012228254A5 (2)	2013-06-27
RU2017132895A (ru)	2019-03-25	Фармацевтическая композиция для лечения рака, содержащая микроРНК в качестве активного ингредиента
NZ616512A (en)	2015-05-29	Modulation of hepatitis b virus (hbv) expression
JP2015502365A5 (2)	2017-06-15
JP2018512041A5 (2)	2019-02-14
JP2014521310A5 (2)	2015-07-09
JP2017505623A5 (2)	2018-03-01
RU2016140897A (ru)	2018-04-19	Композиции для модуляции экспрессии атаксина 2
HRP20191232T1 (hr)	2019-11-01	Inhibicija, posredovana rna interferencijom, ekspresije gena virusa hepatitisa b (hbv) korištenjem kratkih interferirajućih nukleinskih kiselina (sina)
JP2014530004A5 (2)	2015-02-05